Kang Highlights Considerations for the Integration of Torpialimab into Nasopharyngeal Carcinoma Clinical Practice

Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma and his anticipated use of the agent.

Related Keywords

San Francisco ,California ,United States ,Coherus Biosciences ,Caroline Seymour ,Hyunseok Hyu Kang ,Facebook ,Linkedin ,University Of California ,Twitter ,Live On Air ,Onclive On Air ,Apple Podcasts ,Google Podcasts ,Amazon Music ,